APLS
USDApellis Pharmaceuticals Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$20.400
Haut
$20.610
Bas
$19.440
Volume
5.10M
Fondamentaux de l'Entreprise
Capitalisation Boursière
2.5B
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
2.51M
Bourse
NMS
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $19
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals with a Neutral and lowers the price target from $24 to $19.
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $52 to $45.
TD Cowen Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $50 to $45.
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $52
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals with a Outperform and raises the price target from $50 to $52.
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $57 to $45.
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary
Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32
Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals from Equal-Weight to Overweight and raises the price target from $29 to $32.
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.